Our top pick for
Henry Schein, Inc is a medical distribution business based in the US. Henry Schein shares (HSIC) are listed on the NASDAQ and all prices are listed in US Dollars. Henry Schein employs 19,000 staff and has a trailing 12-month revenue of around USD$10.1 billion.
|52-week range||USD$41.85 - USD$74.89|
|50-day moving average||USD$69.2715|
|200-day moving average||USD$65.5492|
|Wall St. target price||USD$74.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.817|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Henry Schein stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Henry Schein's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Henry Schein's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Henry Schein shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Henry Schein's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1059. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Henry Schein's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Henry Schein's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$752.9 million.
The EBITDA is a measure of a Henry Schein's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$10.1 billion|
|Operating margin TTM||5.61%|
|Gross profit TTM||USD$2.8 billion|
|Return on assets TTM||4.75%|
|Return on equity TTM||10.17%|
|Market capitalisation||USD$9.3 billion|
TTM: trailing 12 months
There are currently 4.5 million Henry Schein shares held short by investors – that's known as Henry Schein's "short interest". This figure is 12.8% down from 5.1 million last month.
There are a few different ways that this level of interest in shorting Henry Schein shares can be evaluated.
Henry Schein's "short interest ratio" (SIR) is the quantity of Henry Schein shares currently shorted divided by the average quantity of Henry Schein shares traded daily (recently around 720377.68860353). Henry Schein's SIR currently stands at 6.23. In other words for every 100,000 Henry Schein shares traded daily on the market, roughly 6230 shares are currently held short.
However Henry Schein's short interest can also be evaluated against the total number of Henry Schein shares, or, against the total number of tradable Henry Schein shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Henry Schein's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Henry Schein shares in existence, roughly 30 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable Henry Schein shares, roughly 41 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Henry Schein.
Find out more about how you can short Henry Schein stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Henry Schein.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 12.4
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Henry Schein's overall score of 12.4 (as at 01/01/2019) is excellent – landing it in it in the 9th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Henry Schein is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Henry Schein's environmental score of 3.15 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Henry Schein is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 3.68/100
Henry Schein's social score of 3.68 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Henry Schein is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 4.07/100
Henry Schein's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Henry Schein is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Henry Schein scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Henry Schein has, for the most part, managed to keep its nose clean.
|Total ESG score||12.4|
|Total ESG percentile||8.86|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
We're not expecting Henry Schein to pay a dividend over the next 12 months.
Henry Schein's shares were split on a 1275:1000 basis on 8 February 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1275 shares. This wouldn't directly have changed the overall worth of your Henry Schein shares – just the quantity. However, indirectly, the new 21.6% lower share price could have impacted the market appetite for Henry Schein shares which in turn could have impacted Henry Schein's share price.
Over the last 12 months, Henry Schein's shares have ranged in value from as little as $41.85 up to $74.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Henry Schein's is 0.8442. This would suggest that Henry Schein's shares are less volatile than average (for this exchange).
Henry Schein, Inc., a solutions company for health care professionals, provides health care products and services to office-based dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.